newsIn newly published analysis, Kite's CAR T-cell therapy delivered a…
24 April 2023 | By Catherine Eckford (European Pharmaceutical Review)
In newly published analysis, Kite's CAR T-cell therapy delivered a reduced median European manufacturing turnaround time for diffuse large B-cell lymphoma (DLBCL) patients.